Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.27
+0.0000
Volume:362.90K
Turnover:461.23K
Market Cap:64.44M
PE:-0.54
High:1.31
Open:1.30
Low:1.23
Close:1.27
Loading ...

Cabaletta Bio’s Clinical Progress and Strategic Direction Bolster Buy Rating

TIPRANKS
·
02 Apr

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating

MT Newswires Live
·
01 Apr

Cabaletta Bio Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
01 Apr

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Cabaletta Bio price target lowered to $7 from $10 at UBS

TIPRANKS
·
01 Apr

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating

TIPRANKS
·
01 Apr

Cabaletta Bio Inc : Morgan Stanley Cuts Target Price to $22 From $30

THOMSON REUTERS
·
01 Apr

Cabaletta Bio, Inc. : Wells Fargo Cuts Target Price to $3 From $6

THOMSON REUTERS
·
01 Apr

Cabaletta Bio price target lowered to $13 from $26 at Stifel

TIPRANKS
·
01 Apr

Cabaletta Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
31 Mar

Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024

Benzinga
·
31 Mar

Cabaletta Bio Q4 Net Income USD -32.586 Million

THOMSON REUTERS
·
31 Mar

Cabaletta Bio Q4 Income From Operations USD -33.785 Million

THOMSON REUTERS
·
31 Mar

Cabaletta Bio Q4 Operating Expenses USD 33.785 Million

THOMSON REUTERS
·
31 Mar

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
31 Mar

Cabaletta Bio and Cellares complete TAP for rese-cel using Cell Shuttle

TIPRANKS
·
19 Mar

Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
17 Mar

Promising Clinical Advances and Strategic Developments Justify Buy Rating for Cabaletta Bio

TIPRANKS
·
19 Feb

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Feb

Cabaletta Bio’s Promising Clinical Progress and Strong Buy Rating by Douglas Tsao

TIPRANKS
·
19 Feb